ClinicalTrials.Veeva

Menu

Remote Exercise to Improve Physical Activity Levels and Markers of Heart Health in Cystic Fibrosis (RHH-CF)

U

University of Bath

Status

Not yet enrolling

Conditions

Cystic Fibrosis (CF)
Cardiovascular Disease Risk Factors

Treatments

Other: Lifestyle maintenance
Behavioral: Mobile health exercise programme

Study type

Interventional

Funder types

Other

Identifiers

NCT07027553
7241-11903

Details and patient eligibility

About

With advances in genetic therapies, many people with Cystic Fibrosis (CF) are living longer. With the improvement in life expectancy has emerged an increased risk of cardiovascular disease (CVD). Factors such as insulin resistance, reduced physical activity, rising blood pressure from newer medications, and changes in body mass index have made cardiovascular health a growing concern in CF care.

This study aims to assess whether a remotely delivered, monitored exercise programme can increase physical activity levels in adults with CF. Secondary outcomes will explore whether the intervention improves key CVD risk factors. Participants will be randomly assigned to either a control group or an intervention group, which will complete an 8-week home-based aerobic and resistance exercise programme. Exercise intensity will be tailored using the Rate of Perceived Exertion scale.

Key outcomes include weekly physical activity levels, body mass index, waist circumference, lung function (spirometry) and blood biomarkers. Home-based capillary blood tests, analysed pre- and post-intervention, will measure cholesterol, lipid profiles, inflammation and other relevant hormones.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Past diagnosis of Cystic Fibrosis confirmed via two copies of a faulty CFTR gene, or; previous sweat chloride test with a result >60mmol/L chloride, or; prescribed modulator therapy (Orkambi, Symkevi, Kaftrio);

Exclusion criteria

  • Any reported condition, behaviour or reported use of substances which may pose undue personal risk to the participant or introduce bias into the study, except for any which are ubiquitous in society and so would be equally distributed between groups and/or therefore relevant to generalisation (e.g. caffeine)
  • Medications which increase risk of harm to a participant exercising remotely such as fluoroquinolone antibiotics, beta blockers, or blood pressure medication
  • Individuals with unstable or poorly controlled diabetes
  • Individuals on statins
  • Females who are pregnant or lactating
  • Individuals with a previous self-reported history of an eating disorder
  • Individuals unable to provide informed consent e.g. inability to read or speak English
  • Individuals who are not weight stable (i.e. >3kg change in body mass in the past 3 months)
  • Individuals awaiting a solid organ transplant, have a diagnosis of pulmonary hypertension or require long term oxygen therapy to exercise at home
  • Individuals with chest pain, dizziness or loss of consciousness during exercise, who have been instructed by a doctor to only do certain types/quantity of physical activity
  • Individuals on any current ongoing medication or treatment for injuries or illness which impact on their ability to do physical tasks or exercises
  • Individuals who are PAR-Q positive response during screening

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

30 participants in 2 patient groups

Intervention
Experimental group
Treatment:
Behavioral: Mobile health exercise programme
Control
Active Comparator group
Treatment:
Other: Lifestyle maintenance

Trial contacts and locations

1

Loading...

Central trial contact

Rachel C McDowell

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems